文献速递泌尿生殖介入腹部CT

T1a期肾细胞癌经皮微波消融:119个肿瘤的安全性、技术可行性与临床结局中期结果

Percutaneous Microwave Ablation of Category T1a Renal Cell Carcinoma: Intermediate Results on Safety, Technical Feasibility, and Clinical Outcomes of 119 Tumors.
PubMed 文献 · AJR Am J Roentgenol · 2020-11-19

本回顾性研究纳入2015年10月至2019年5月连续接受CT引导经皮微波消融的T1a期肾细胞癌患者106例共119个肿瘤,技术成功率达100%,完全缓解率95.3%,1、2、3年局部无进展生存率分别为100.0%、92.8%、90.6%,总生存率分别为99.0%、97.7%、94.6%,6例(5.7%)出现7次并发症。作者结论认为CT引导经皮微波消融治疗T1a期肾细胞癌技术成功率高、局部无进展生存率和总生存率优异、并发症率低。

要点

  • CT引导经皮微波消融治疗T1a期肾细胞癌技术成功率达100%。
  • 完全缓解101例(95.3%),部分缓解5例(4.7%)。
  • 6例(5.7%)发生7次并发症,其中Clavien-Dindo I级/SIR A类5次、III级/SIR B类2次。

核心结论

  • CT引导经皮微波消融治疗T1a期肾细胞癌技术成功率高、局部无进展生存率和总生存率优异、并发症率低。

研究设计与样本

  • 回顾性研究,纳入2015年10月至2019年5月连续接受CT引导经皮微波消融的T1a期肾细胞癌患者106例(男70例、女36例)共119个肿瘤,评估肿瘤特征、合并症、技术细节和临床结局,采用Kaplan-Meier法估算局部无进展生存率和总生存率。

诊断标准与关键数值

  • 技术成功率为100%。
  • 完全缓解101例(95.3%),部分缓解5例(4.7%)。
  • 局部无进展生存率1年100.0%、2年92.8%、3年90.6%。
  • 总生存率1年99.0%、2年97.7%、3年94.6%。

临床应用与阅片要点

  • 作者结论认为CT引导经皮微波消融治疗T1a期肾细胞癌技术成功率高、局部无进展生存率和总生存率优异、并发症率低。
  • 6例(5.7%)在术后30天内发生7次并发症,其中Clavien-Dindo I级/SIR A类5次、Clavien-Dindo III级/SIR B类2次。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this study was to assess the safety, technical results, and clinical outcomes of CT-guided percutaneous microwave ablation of category T1a renal cell carcinoma. MATERIALS AND METHODS. This retrospective study investigated consecutive patients who underwent CT-guided microwave ablation for T1a renal cell carcinoma from October 2015 to May 2019. Patient demographics including tumor characteristics, comorbidities, technical details, and clinical outcomes were evaluated. Local progression-free survival and overall survival rates were estimated using the Kaplan-Meier method. RESULTS. One hundred-six patients including 70 men (mean age, 68.5 ± 8.9 [SD] years; range, 49-86 years) and 36 women (mean age, 69.5 ± 10.0 years; range, 50-88 years) with an overall mean age of 68.8 ± 9.2 years (range, 49-88 years) with 119 T1a renal cell carcinomas were treated with CT-guided microwave ablation. Technical success was achieved for 100% of the tumors. Complete response was achieved in 101 (95.3%) patients and partial response was achieved in five (4.7%) patients. Local progression-free survival was 100.0%, 92.8%, and 90.6% at 1, 2, and 3 years, respectively. Overall survival was 99.0%, 97.7%, and 94.6% at 1, 2, and 3 years, respectively. Six patients (5.7%) had seven complications (five with Clavien-Dindo Grade I, Society of Interventional Radiology [SIR] category A, two with Clavien-Dindo Grade III, SIR category B) within 30 days of the procedure. CONCLUSION. CT-guided percutaneous microwave ablation is associated with high rates of technical success, excellent local progression-free survival and overall survival, and a low complication rate for category T1a renal cell carcinoma.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Guo J, Arellano RS. Percutaneous Microwave Ablation of Category T1a Renal Cell Carcinoma: Intermediate Results on Safety, Technical Feasibility, and Clinical Outcomes of 119 Tumors. AJR Am J Roentgenol. 2020. PMID: 32603227. doi:10.2214/AJR.20.22818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。